Mankind Pharma Peer Comparison
NSE: MANKIND | BSE: 543904
₹2,626.60
As on 16-Nov-2026IST
Market cap
₹1,08,424 Cr
Revenue (TTM)
₹15,379 Cr
P/E Ratio
48.3
P/B Ratio
6.2
Div. Yield
0 %
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
1,08,424 | 1,18,603 | 1,15,267 | 1,02,878 | 90,201 |
Revenue (₹ Cr) |
15,379 | 30,378 | 33,097 | 36,913 | 30,746 |
Net Profit (₹ Cr) |
2,249.69 | 4,159.00 | 2,759.70 | 3,993.05 | 5,221.47 |
Net Margin (%) |
14.32 | 13.20 | 8.03 | 10.61 | 16.70 |
RoE (%) |
13.86 | 16.61 | 7.30 | 10.51 | 24.24 |
Price to Earnings |
48.35 | 28.37 | 41.17 | 25.78 | 17.33 |
Price-To-Book |
6.17 | 4.26 | 2.97 | 2.61 | 3.75 |
Income Statement (₹ Cr)
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Operating Revenue
|
15,378.58 | 30,378.10 | 33,097.40 | 36,912.88 | 30,746.33 |
|
Total Income
|
15,705.47 | 31,504.60 | 34,352.50 | 37,650.01 | 31,258.85 |
|
Total Expenditure
|
11,301.83 | 22,828.30 | 28,236.90 | 29,349.95 | 21,504.94 |
|
EBITDA
|
4,076.75 | 7,549.80 | 4,860.50 | 7,562.93 | 9,241.39 |
|
Depreciation
|
907.11 | 2,027.20 | 2,141.40 | 1,961.27 | 1,698.50 |
|
EBIT
|
3,169.64 | 5,522.60 | 2,719.10 | 5,601.66 | 7,542.89 |
|
Interest
|
513.87 | 595.90 | 450.40 | 394.85 | 450.49 |
|
Other Income
|
326.89 | 1,126.50 | 1,255.10 | 737.13 | 512.52 |
|
Exceptional Items
|
-129.75 | -499.30 | 0.00 | -105.51 | -557.91 |
|
Profit before Tax
|
2,852.91 | 5,553.90 | 3,523.80 | 5,838.43 | 7,047.01 |
|
Provision for Tax
|
603.22 | 1,394.90 | 764.10 | 1,845.38 | 1,825.54 |
|
Profit after Tax
|
2,249.69 | 4,159.00 | 2,759.70 | 3,993.05 | 5,221.47 |
Liabilities (₹ Cr)
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
17,582.22 | 27,817.30 | 38,807.00 | 39,399.90 | 24,050.46 |
|
Minority Interest
|
-20.87 | -101.90 | 40.20 | 3.68 | -15.31 |
|
Non-Current Liabilities
|
5,214.33 | 7,260.60 | 3,074.90 | 2,689.12 | 3,318.63 |
|
Current Liabilities
|
5,884.79 | 18,023.50 | 15,430.30 | 19,667.17 | 12,541.26 |
|
Total Liabilities
|
27,754.83 | 50,672.60 | 56,576.70 | 58,196.15 | 38,146.06 |
Assets (₹ Cr)
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
20,096.89 | 36,142.90 | 26,891.10 | 26,331.59 | 14,387.96 |
|
Current Assets
|
7,956.27 | 18,433.50 | 29,732.20 | 33,958.66 | 23,070.16 |
|
Total Assets
|
27,754.83 | 50,672.60 | 56,576.70 | 58,196.15 | 38,146.06 |
|
Total Debt*
|
6,021.78 | 11,769.50 | 7,734.10 | 7,676.20 | 5,910.20 |
|
Net Current Assets
|
2,071.48 | 410.00 | 14,301.90 | 14,291.49 | 10,528.90 |
|
Contingent Liabilities
|
924.77 | 989.90 | 336.14 | 1,358.37 | 1,094.02 |
Cashflow (₹ Cr)
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,121.29 | 2,116.60 | 5,673.70 | 5,526.37 | 7,334.50 |
|
Cash Flow from Investing Activities
|
-196.42 | -8,296.10 | -6,549.30 | -3,458.61 | -3,864.59 |
|
Cash from Financing Activities
|
-2,952.69 | 5,806.90 | 829.00 | -1,269.15 | -845.87 |
|
Net Cash Inflow / Outflow
|
-27.82 | -372.60 | -46.60 | 798.61 | 2,624.04 |
Ratios
Profitability Ratios
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
ROCE (%)
|
13.24 | 21.39 | 13.75 | 12.76 | 28.86 |
|
ROE (%)
|
13.86 | 16.61 | 7.30 | 10.51 | 24.24 |
|
ROA (%)
|
7.79 | 8.11 | 4.93 | 6.99 | 14.23 |
|
EBIT Margin (%)
|
20.61 | 18.18 | 8.22 | 15.18 | 24.53 |
|
Net Margin (%)
|
14.32 | 13.20 | 8.03 | 10.61 | 16.70 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
13.53 | 24.02 | -3.53 | 13.53 | 24.22 |
|
EBIT Growth (%)
|
31.59 | -16.48 | -58.47 | 13.09 | 38.02 |
|
Net Profit Growth (%)
|
27.79 | -16.41 | -51.77 | 15.82 | 20.10 |
|
EPS Growth (%)
|
34.22 | -10.25 | -51.50 | 19.29 | 30.16 |
|
Book Value Growth (%)
|
13.74 | 13.19 | 12.99 | 16.04 | 30.75 |
Valuation Ratios
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Price / Earnings
|
46.16 | 26.13 | 41.14 | 25.44 | 16.00 |
|
Price / Book Value
|
6.17 | 4.26 | 2.97 | 2.61 | 3.75 |
|
Dividend Yield (%)
|
0.04 | 0.08 | 0.58 | 0.22 | 0.91 |
|
EV/EBITDA
|
27.58 | 16.32 | 23.86 | 13.21 | 9.40 |
|
Market Cap (₹ Cr)
|
82,801.75 | 87,643.18 | 1,04,763.81 | 75,689.14 | 1,05,737.27 |
Solvency Ratios
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.17 | 0.15 | 0.00 | 0.02 | 0.06 |
|
Short term debt to equity ratio
|
0.04 | 0.16 | 0.16 | 0.16 | 0.18 |
|
Current Ratio
|
1.35 | 1.02 | 1.93 | 1.73 | 1.84 |
|
Quick Ratio
|
0.95 | 0.64 | 1.40 | 1.06 | 1.32 |
|
Interest Coverage
|
6.55 | 10.32 | 8.82 | 15.79 | 16.64 |
Operating Efficiency Ratios
| Mankind Pharma | Zydus Lifesciences | Dr. Reddy'S Labs | Aurobindo Pharma | Lupin | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.17 | 14.42 | 30.64 | 20.44 | 21.65 |
|
Asset Turnover
|
0.53 | 0.59 | 0.59 | 0.65 | 0.84 |
|
Receivable days
|
39.93 | 33.55 | 103.79 | 33.71 | 51.23 |
|
Inventory Days
|
51.78 | 33.80 | 79.94 | 59.32 | 48.93 |
|
Payable days
|
111.46 | 149.82 | 84.78 | 148.20 | 205.75 |
|
Cash Conversion Cycle
|
-19.75 | -82.46 | 98.95 | -55.17 | -105.59 |